AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 35441839 — intervention group
Group type: COMPARATOR
Intervention: Single-energy computed tomography (SECT) with TVA (n = 40, ref. mAs 200)
Number of subjects: 80
Study 35441839 — intervention group
Group type: COMPARATOR
Intervention: Single-energy computed tomography (SECT) with TVA (n = 40)
Number of subjects: 80
Study 34134048 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal exposure to carbon monoxide (CO) during pregnancy
Number of subjects: 1288
Study 36279142 — intervention group
Group type: EXPERIMENTAL
Intervention: Mask group (students instructed to wear their own masks at all times)
Number of subjects: 171
Study 36279142 — intervention group
Group type: EXPERIMENTAL
Intervention: Mask group
Number of subjects: 171
Study 36279142 — intervention group
Group type: COMPARATOR
Intervention: Control group (students not required to wear masks)
Number of subjects: 171
Study 34531293 — intervention group
Group type: COMPARATOR
Intervention: Conventional Lifestyle Intervention (LI) according to the Diabetes Prevention Program (DPP) protocol
Number of subjects: 1105
Study 34531293 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensified Lifestyle Intervention (LI) with doubling of required exercise
Number of subjects: 1105
Study 34581025 — intervention group
Group type: EXPERIMENTAL
Intervention: AS04-HPV-16/18 vaccine (90% of Arm A and 90% of Arm B girls)
Number of subjects: 34412
Study 34581025 — intervention group
Group type: EXPERIMENTAL
Intervention: AS04-HPV-16/18 vaccine (90% of Arm B girls)
Number of subjects: 34412
Study 34581025 — intervention group
Group type: EXPERIMENTAL
Intervention: AS04-HPV-16/18 vaccine (in pooled Arms A/B)
Number of subjects: 34412
Study 34581025 — intervention group
Group type: COMPARATOR
Intervention: HBV vaccine (10% of Arm A girls and all boys in Arm B, all participants in Arm C)
Number of subjects: 34412
Study 32034015 — intervention group
Group type: EXPERIMENTAL
Intervention: Balloon pulmonary angioplasty (BPA)
Number of subjects: 0
Study 32034015 — intervention group
Group type: COMPARATOR
Intervention: Riociguat (a soluble guanylate-cyclase stimulator)
Number of subjects: 0
Study 33715265 — intervention group
Group type: EXPERIMENTAL
Intervention: Late onset dysferlinopathy patients
Number of subjects: 48
Study 33715265 — intervention group
Group type: COMPARATOR
Intervention: Early onset dysferlinopathy patients (control group)
Number of subjects: 48
Study 32280072 — intervention group
Group type: EXPERIMENTAL
Intervention: Fresnel prism glasses with balance and gait training (n=8)
Number of subjects: 17
Study 32280072 — intervention group
Group type: COMPARATOR
Intervention: Balance and gait training (n=9)
Number of subjects: 17
Study 33789010 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumasiran
Number of subjects: 39
Study 33789010 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 35742702 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive non-surgical periodontal therapy (MINST)
Number of subjects: 10
Study 35742702 — intervention group
Group type: COMPARATOR
Intervention: Conventional non-surgical periodontal therapy (CNST)
Number of subjects: 10
Study 34866216 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluralaner (oral dose)
Number of subjects: 72
Study 34866216 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 72
Study 33017529 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride toothpaste with 20% baking soda
Number of subjects: 159
Study 33017529 — intervention group
Group type: COMPARATOR
Intervention: Fluoride toothpaste control
Number of subjects: 159
Study 34370994 — intervention group
Group type: EXPERIMENTAL
Intervention: Dacryocystorhinostomy with retrograde intubation
Number of subjects: 50
Study 34370994 — intervention group
Group type: COMPARATOR
Intervention: Conjunctivo‐dacryocystorhinostomy
Number of subjects: 50
Study 33124156 — intervention group
Group type: EXPERIMENTAL
Intervention: Artificial dermis combined with autologous split-thickness skin grafting (AD-STSG)
Number of subjects: 56
Study 33124156 — intervention group
Group type: COMPARATOR
Intervention: Autologous intermediate-thickness skin grafting (ITSG)
Number of subjects: 56
Study 32946590 — intervention group
Group type: EXPERIMENTAL
Intervention: XBS + 10 × 10^6 PDL-MSCs/100 mg
Number of subjects: 20
Study 32946590 — intervention group
Group type: COMPARATOR
Intervention: XBS
Number of subjects: 20
Study 34538125 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional bed bath
Number of subjects: 0
Study 34538125 — intervention group
Group type: EXPERIMENTAL
Intervention: Disposable bed bath
Number of subjects: 0
Study 34538125 — intervention group
Group type: COMPARATOR
Intervention: Both bathing methods
Number of subjects: 0
Study 33893377 — intervention group
Group type: EXPERIMENTAL
Intervention: myo‐inositol plus α‐lactalbumin plus folic acid
Number of subjects: 120
Study 33893377 — intervention group
Group type: COMPARATOR
Intervention: folic acid
Number of subjects: 120
Study 33267668 — intervention group
Group type: EXPERIMENTAL
Intervention: Handgrip strength test
Number of subjects: 234
Study 33267668 — intervention group
Group type: COMPARATOR
Intervention: Standardized muscular strength tests (reference methods)
Number of subjects: 234
Study 35534312 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradermal fractional-dose inactivated polio vaccine (fIPV) adjuvanted with dmLT
Number of subjects: 0
Study 35534312 — intervention group
Group type: COMPARATOR
Intervention: Fractionated dose of intradermal IPV without dmLT
Number of subjects: 0
Study 32865597 — intervention group
Group type: EXPERIMENTAL
Intervention: Dulaglutide (weekly for 24 weeks)
Number of subjects: 64
Study 33731569 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium hydroxylapatite with lidocaine (3 mL total, 1 to 2 syringes)
Number of subjects: 10
Study 33731569 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium hydroxylapatite (treated side)
Number of subjects: 10
Study 34156873 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based telerehabilitation (TR)
Number of subjects: 59
Study 34156873 — intervention group
Group type: COMPARATOR
Intervention: In-clinic therapy
Number of subjects: 59
Study 32819145 — intervention group
Group type: EXPERIMENTAL
Intervention: Conscious Sedation (CS)
Number of subjects: 447
Study 32819145 — intervention group
Group type: COMPARATOR
Intervention: General Anesthesia (GA)
Number of subjects: 447
Study 34605319 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofatumumab (20 mg every 4 weeks, subcutaneous via autoinjector)
Number of subjects: 256
Study 34605319 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofatumumab (20 mg every 4 weeks, subcutaneous via PFS)
Number of subjects: 256
Study 34605319 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups receiving ofatumumab (autoinjector and PFS)
Number of subjects: 256
Study 34605319 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofatumumab (both administration methods)
Number of subjects: 256
Study 32435011 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual lipid‐lowering therapy (DLLT) with ezetimibe and atorvastatin
Number of subjects: 25
Study 32435011 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin monotherapy
Number of subjects: 25
Study 32770186 — intervention group
Group type: EXPERIMENTAL
Intervention: e-learning module about pain in dementia during a geriatrics course
Number of subjects: 161
Study 32770186 — intervention group
Group type: COMPARATOR
Intervention: e-learning module about pain in dementia without the context of a geriatrics course
Number of subjects: 161
Study 32770186 — intervention group
Group type: COMPARATOR
Intervention: Control module on pain during a geriatrics course
Number of subjects: 161
Study 32770186 — intervention group
Group type: EXPERIMENTAL
Intervention: Experiential learning (geriatrics course)
Number of subjects: 161
Study 32770186 — intervention group
Group type: EXPERIMENTAL
Intervention: Both e-learning and experiential learning
Number of subjects: 161
Study 35654052 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibrutinib plus venetoclax (ibrutinib: 420 mg once daily; venetoclax: weekly ramp-up from 20 mg to 400 mg once daily)
Number of subjects: 225
Study 35654052 — intervention group
Group type: COMPARATOR
Intervention: Ibrutinib maintenance
Number of subjects: 225
Study 35654052 — intervention group
Group type: COMPARATOR
Intervention: Treatment cessation
Number of subjects: 225
Study 35654052 — intervention group
Group type: COMPARATOR
Intervention: Ibrutinib monotherapy (for patients not randomly assigned)
Number of subjects: 225
Study 32019598 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous paracetamol
Number of subjects: 20
Study 32019598 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous paracetamol
Number of subjects: 20
Study 36314570 — intervention group
Group type: EXPERIMENTAL
Intervention: Forced Awakening (FA)
Number of subjects: 95
Study 36314570 — intervention group
Group type: COMPARATOR
Intervention: Undisturbed Sleep (US)
Number of subjects: 95
Study 33130949 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy dietary pattern
Number of subjects: 35175
Study 33130949 — intervention group
Group type: EXPERIMENTAL
Intervention: Animal food dietary pattern
Number of subjects: 35175
Study 33130949 — intervention group
Group type: EXPERIMENTAL
Intervention: Sweet dietary pattern
Number of subjects: 35175
Study 33228006 — intervention group
Group type: EXPERIMENTAL
Intervention: Any intervention arm
Number of subjects: 234
Study 33228006 — intervention group
Group type: COMPARATOR
Intervention: Control arm
Number of subjects: 234
Study 35767384 — intervention group
Group type: EXPERIMENTAL
Intervention: Remestemcel-L (150 million MSCs)
Number of subjects: 6
Study 35767384 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 34177385 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-week at-home positive psychology intervention
Number of subjects: 30
Study 34177385 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control condition
Number of subjects: 30
Study 33368307 — intervention group
Group type: EXPERIMENTAL
Intervention: Tezepelumab 210 mg subcutaneously every 4 weeks
Number of subjects: 0
Study 33368307 — intervention group
Group type: EXPERIMENTAL
Intervention: Tezepelumab doses up to 280 mg every 2 weeks
Number of subjects: 0
Study 32861841 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-focused therapy
Number of subjects: 126
Study 36091030 — intervention group
Group type: COMPARATOR
Intervention: Celecoxib 200 mg bid
Number of subjects: 150
Study 36091030 — intervention group
Group type: COMPARATOR
Intervention: Etanercept 50 mg qw
Number of subjects: 150
Study 36091030 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy (etanercept + celecoxib)
Number of subjects: 150
Study 34047371 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane
Number of subjects: 101
Study 34047371 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 101
Study 32879960 — intervention group
Group type: EXPERIMENTAL
Intervention: Conditional cash transfer (CCT) programme
Number of subjects: 790
Study 35766128 — intervention group
Group type: EXPERIMENTAL
Intervention: Nemolizumab 0.5 mg/kg SC
Number of subjects: 70
Study 33882446 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile phone app-based training plus routine care for 12 weeks
Number of subjects: 0
Study 33882446 — intervention group
Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 0
Study 34196132 — intervention group
Group type: EXPERIMENTAL
Intervention: MA-Bu regimen
Number of subjects: 224
Study 34196132 — intervention group
Group type: COMPARATOR
Intervention: MA-Bu vs. MA-TBI vs. RIST-Bu
Number of subjects: 224
Study 34196132 — intervention group
Group type: COMPARATOR
Intervention: MA-Bu vs. MA-TBI
Number of subjects: 224
Study 34196132 — intervention group
Group type: COMPARATOR
Intervention: Oral busulfan vs. intravenous busulfan
Number of subjects: 224
Study 34962561 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg of aspirin once daily
Number of subjects: 15480
Study 34962561 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo for aspirin
Number of subjects: 15480
Study 34962561 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g of ω-3 fatty acids once daily
Number of subjects: 15480
Study 34962561 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo for ω-3 fatty acids
Number of subjects: 15480
Study 36012078 — intervention group
Group type: EXPERIMENTAL
Intervention: ETUCARE online self-help program (n = 53)
Number of subjects: 103
Study 36012078 — intervention group
Group type: COMPARATOR
Intervention: Control condition (n = 50)
Number of subjects: 103
Study 32067691 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-month trastuzumab treatment
Number of subjects: 481
Study 32067691 — intervention group
Group type: COMPARATOR
Intervention: 6-month trastuzumab treatment
Number of subjects: 481
Study 36100672 — intervention group
Group type: EXPERIMENTAL
Intervention: Esaxerenone
Number of subjects: 0
Study 33908288 — intervention group
Group type: EXPERIMENTAL
Intervention: Single structured early palliative care intervention
Number of subjects: 150
Study 33908288 — intervention group
Group type: COMPARATOR
Intervention: Usual oncology care
Number of subjects: 150
Study 32889373 — intervention group
Group type: EXPERIMENTAL
Intervention: Fingolimod 0.5mg
Number of subjects: 0
Study 32889373 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 33095469 — intervention group
Group type: COMPARATOR
Intervention: FFC-AL-EIT intervention implemented by a function focused care nurse facilitator over 12 months.
Number of subjects: 550
Study 33095469 — intervention group
Group type: COMPARATOR
Intervention: FFC-AL-EIT intervention
Number of subjects: 550
Study 32569024 — intervention group
Group type: EXPERIMENTAL
Intervention: Atypical glandular cell (AGC) Pap tests with abnormal uterine bleeding
Number of subjects: 478
Study 32569024 — intervention group
Group type: EXPERIMENTAL
Intervention: Atypical glandular cell (AGC) Pap tests with HPV positivity
Number of subjects: 478
Study 32569024 — intervention group
Group type: COMPARATOR
Intervention: AGC Pap tests
Number of subjects: 478
Study 35265304 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine sequential treatment for 4 cycles
Number of subjects: 100
Study 35265304 — intervention group
Group type: COMPARATOR
Intervention: Control group (no sequential treatment)
Number of subjects: 100
Study 32100452 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential boost of intensity-modulated radiation therapy (IMRT) with chemotherapy (fluorouracil 600 mg/m2 days 1-3 and cisplatin 25 mg/m2 days 1-3, every 4 weeks for 4 cycles)
Number of subjects: 88
Study 32100452 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential boost of intensity-modulated radiation therapy (IMRT) with chemotherapy
Number of subjects: 88
Study 36071284 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic equilibrium gait training (DEGT) for 6 weeks
Number of subjects: 70
Study 36071284 — intervention group
Group type: COMPARATOR
Intervention: Standard exercise (SE) for 6 weeks
Number of subjects: 70
Study 36071284 — intervention group
Group type: COMPARATOR
Intervention: Natural course (NC)
Number of subjects: 70
Study 34480060 — intervention group
Group type: EXPERIMENTAL
Intervention: Microparticles and PD1 expressions in MM patients
Number of subjects: 30
Study 34480060 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy participants)
Number of subjects: 30
Study 34480060 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients who did not achieve complete response
Number of subjects: 30
Study 34134521 — intervention group
Group type: EXPERIMENTAL
Intervention: Cradle hold position
Number of subjects: 67
Study 34134521 — intervention group
Group type: COMPARATOR
Intervention: Football hold position
Number of subjects: 67
Study 34134521 — intervention group
Group type: EXPERIMENTAL
Intervention: Both positions
Number of subjects: 67
Study 35863669 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone (0.5mg/kg/day, maximum 40mg/day, for 14±2 days)
Number of subjects: 27
Study 34459060 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep-extension programme based on cognitive behavioural principles (n=10)
Number of subjects: 18
Study 33714568 — intervention group
Group type: EXPERIMENTAL
Intervention: GAC silicone ligatures (in vivo)
Number of subjects: 20
Study 33714568 — intervention group
Group type: EXPERIMENTAL
Intervention: GAC silicone ligatures (in vitro)
Number of subjects: 20
Study 33714568 — intervention group
Group type: COMPARATOR
Intervention: Other ligature groups (in vivo and in vitro)
Number of subjects: 20
Study 35410445 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity aerobic training for 16 weeks (32 sessions)
Number of subjects: 0
Study 35410445 — intervention group
Group type: COMPARATOR
Intervention: Control group (details not specified)
Number of subjects: 0
Study 34297360 — intervention group
Group type: EXPERIMENTAL
Intervention: Survivors diagnosed in 1954-1969
Number of subjects: 8886
Study 34297360 — intervention group
Group type: EXPERIMENTAL
Intervention: Survivors diagnosed in the 1970s
Number of subjects: 8886
Study 34297360 — intervention group
Group type: EXPERIMENTAL
Intervention: Survivors diagnosed in the 1980s
Number of subjects: 8886
Study 34297360 — intervention group
Group type: EXPERIMENTAL
Intervention: Survivors diagnosed in the 1990s
Number of subjects: 8886
Study 34297360 — intervention group
Group type: EXPERIMENTAL
Intervention: Survivors diagnosed in the 2000s
Number of subjects: 8886
Study 34297360 — intervention group
Group type: COMPARATOR
Intervention: General population (control group)
Number of subjects: 8886
Study 32493552 — intervention group
Group type: EXPERIMENTAL
Intervention: Scopolamine treatment
Number of subjects: 0
Study 32493552 — intervention group
Group type: COMPARATOR
Intervention: Nontreated group
Number of subjects: 0
Study 35028170 — intervention group
Group type: EXPERIMENTAL
Intervention: Chamomile extract cream
Number of subjects: 73
Study 35028170 — intervention group
Group type: COMPARATOR
Intervention: Clotrimazole vaginal cream
Number of subjects: 73
Study 33022056 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal Outcome Score for Epistaxis (NOSE HHT)
Number of subjects: 401
Study 36445843 — intervention group
Group type: EXPERIMENTAL
Intervention: ORSIM (high-fidelity task trainer)
Number of subjects: 24
Study 36445843 — intervention group
Group type: COMPARATOR
Intervention: Wooden-block (low-fidelity task trainer)
Number of subjects: 24
Study 33046528 — intervention group
Group type: EXPERIMENTAL
Intervention: i-gel
Number of subjects: 80
Study 33046528 — intervention group
Group type: EXPERIMENTAL
Intervention: laryngeal mask airway
Number of subjects: 80
Study 33046528 — intervention group
Group type: EXPERIMENTAL
Intervention: endotracheal tube
Number of subjects: 80
Study 33046528 — intervention group
Group type: COMPARATOR
Intervention: laryngeal mask airway and i-gel
Number of subjects: 80
Study 35850871 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital dentures
Number of subjects: 16
Study 35850871 — intervention group
Group type: COMPARATOR
Intervention: Conventional dentures
Number of subjects: 16
Study 33175143 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomogram based on AJCC T, N stage, bone metastases, brain metastases, and liver metastases as predictors.
Number of subjects: 16059
Study 33175143 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomogram including mixed histological types, chemotherapy, and primary site surgery as factors.
Number of subjects: 16059
Study 35946018 — intervention group
Group type: EXPERIMENTAL
Intervention: Preanesthetic fluid loading with Ringer's lactate (20 mL/kg over 30 minutes)
Number of subjects: 60
Study 35946018 — intervention group
Group type: COMPARATOR
Intervention: No preloading (2 mL/kg/h maintenance)
Number of subjects: 60
Study 32805028 — intervention group
Group type: EXPERIMENTAL
Intervention: Avocado consumption (175 g for men; 140 g for women) once daily for 12 weeks
Number of subjects: 163
Study 32805028 — intervention group
Group type: EXPERIMENTAL
Intervention: Avocado consumption
Number of subjects: 163
Study 32805028 — intervention group
Group type: COMPARATOR
Intervention: Control group (no avocado)
Number of subjects: 163
Study 32693198 — intervention group
Group type: EXPERIMENTAL
Intervention: REAL media program
Number of subjects: 639
Study 32693198 — intervention group
Group type: COMPARATOR
Intervention: Control (delayed program use)
Number of subjects: 639
Study 35524695 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily fortified balanced energy-protein supplement and an iron-folic acid (IFA) tablet
Number of subjects: 1757
Study 35524695 — intervention group
Group type: COMPARATOR
Intervention: IFA tablet only
Number of subjects: 1757
Study 33650326 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot-assisted vitreoretinal surgery
Number of subjects: 8
Study 33650326 — intervention group
Group type: COMPARATOR
Intervention: Manual surgery
Number of subjects: 8
Study 32917847 — intervention group
Group type: EXPERIMENTAL
Intervention: PEEP (Positive End-Expiratory Pressure)
Number of subjects: 417
Study 32917847 — intervention group
Group type: COMPARATOR
Intervention: No PEEP (Control)
Number of subjects: 417
Study 34068687 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-Calorie Diet (LCD) 800 kcal/day for 8 weeks
Number of subjects: 782
Study 34147829 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid ASC-ICO algorithm
Number of subjects: 244
Study 34147829 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid BA-ICO algorithm
Number of subjects: 244
Study 34147829 — intervention group
Group type: COMPARATOR
Intervention: Standalone ICO algorithm
Number of subjects: 244
Study 34147829 — intervention group
Group type: COMPARATOR
Intervention: Hybrid AR-ICO algorithm
Number of subjects: 244
Study 33256337 — intervention group
Group type: EXPERIMENTAL
Intervention: Changsulin®
Number of subjects: 578
Study 33256337 — intervention group
Group type: COMPARATOR
Intervention: Lantus®
Number of subjects: 578
Study 35672586 — intervention group
Group type: EXPERIMENTAL
Intervention: Exclusive Enteral Nutrition (EEN)
Number of subjects: 47
Study 35672586 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroids
Number of subjects: 47
Study 33523106 — intervention group
Group type: EXPERIMENTAL
Intervention: AA:DHA supplementation (100 mg/kg/d of AA and 50 mg/kg/d of DHA)
Number of subjects: 206
Study 33523106 — intervention group
Group type: EXPERIMENTAL
Intervention: AA:DHA supplementation
Number of subjects: 206
Study 33523106 — intervention group
Group type: COMPARATOR
Intervention: Control (no supplementation)
Number of subjects: 206
Study 34269503 — intervention group
Group type: EXPERIMENTAL
Intervention: NC + 5% HNa + 1% Gln
Number of subjects: 40
Study 34269503 — intervention group
Group type: COMPARATOR
Intervention: NC
Number of subjects: 40
Study 35765137 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain drawings interpretation by clinicians
Number of subjects: 98